Brian F. Gage, M.D., MSc
Department of Internal Medicine
Washington University School of Medicine
Barnes-Jewish Hospital Blood Thinner Service

Contents:

• Anticoagulants for Stroke Prophylaxis
• Warfarin
• Clotting Cascade
• Risk Factors for Hemorrhage During Warfarin Therapy
• Relationship of Protime Ratio to International Normalized Ratio (INR)
• 2º Prevention: After a Prior Cardio-Embolic Stroke
• 2º Prevention: Stroke Prevention in Reversible Ischemia Trial (SPIRIT)
• Atrial Fibrillation: Results of RCT’s, Warf. vs. No Rx
• Atrial Fibrillation: Results of RCT’s, No Rx vs. ASA
• Atrial Fibrillation: Stroke Rate with Warfarin and Antiplatlet Therapy
• Atrial Fibrillation: Findings of RCTs
• INR-Specific Incidence Rate of Adverse Event
• Lowest Effective Intensity for Warfarin Therapy for Stroke Prevention in Atrial Fibrillation
• Days Since Index Hospitalization
• Recommendations for Atrial Fibrillation
• Mechanical Valves: Effect of INR on Incidence of Adverse Events
• Effect of ASA on Adverse Events in Patients with Mechanical Valves who are Receiving Warfarin
• Recommendations for Mechanical Valves
• Effect of ASA on Adverse Events in Patients Post-MI (Antiplatelet Trialists' Collaboration)
• Effect of Nicoumalone or Phenprocoumon on Adverse Events in Patients Post-MI (ASPECT)
• Effect of Warfarin on Adverse Events in Patients Post-MI (ASPECT)
• Recommendations for Post-MI Patients
• Summary
• References